DiaPep277 (DeveloGen).

Abstract

DiaPep277, a 24-amino acid peptide based on residues 437 to 460 of heat shock protein 60, is undergoing phase II clinical trials by DeveloGen for the potential treatment and prevention of established and newly diagnosed type 1 diabetes symptoms of the prediabetic state and of latent autoimmune diabetes of the adult.

• Authors: Nick Giannoukakis
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 10 Pg. 1043-50 (Oct 2005) ISSN: 1472-4472 [Print] England
• PMID: 16259226 (Publication Type: Journal Article, Review)

Chemical References

• Chaperonin 60
• DiaPep 277
• Hypoglycemic Agents
• Peptide Fragments
• Peptides

Topics

• Animals
• Chaperonin 60
• Clinical Trials, Phase II as Topic
• Diabetes Mellitus, Type 1 (drug therapy)
• Drug Industry
• Humans
• Hypoglycemic Agents (chemistry, therapeutic use)
• Peptide Fragments
• Peptides (chemistry, therapeutic use)
• Structure-Activity Relationship
• Treatment Outcome